Your search history is turned on.
Date: November 10, 2014 Jurisdictions: British Columbia
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Spec...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2014. Or For the transition period from to . Commission File Number 000-51171 EPIRUS BIOPHARMACEUTICALS, ...
Exhibit 31.2 CERTIFICATIONS I, Thomas Shea, certify that: 1. I have reviewed this quarterly report on Form 10-Q of EPIRUS Biopharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac...
Exhibit 31.1 CERTIFICATIONS I, Amit Munshi, certify that: 1. I have reviewed this quarterly report on Form 10-Q of EPIRUS Biopharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac...
Date: October 31, 2014 Jurisdictions: British Columbia
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in it...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specifi...
Exhibit 99.1 EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China Partners to develop, manufacture and commercialize up to five biosimilars, including EPIRUS BOW015, for Asian markets BOSTON, September 25, 2014 - EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Cha...